Loading…

Qiagen NVQGENCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of sample-preparation and molecular testing technologies for life-science research, applied testing and molecular diagnostics.

Momentum leader 88
Mkt cap
$10.2B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$296M
20-day average traded
Fwd P/E
19.5×
forward earnings
ROIC−WACC
+2.3 pp
WACC 7.5%
Hurdle
+6 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · USD$49.56
1D-0.4%
1W-1.5%
1M+1.4%
3M+10.4%
6M+41.2%
YTD+4.7%
1Y+6.7%
ATR %1.2%
Beta0.33
52w lowhigh14.3% off high

What Qiagen does

Maker of sample-preparation and molecular testing technologies for life-science research, applied testing and molecular diagnostics.

Places instruments in labs and earns mostly on the consumable kits used on them: each test run uses a kit, so the installed base of machines generates repeat purchases. Its QuantiFERON tuberculosis blood test is run as a kit by testing labs. It is Dutch-domiciled, with most sales in the US and Europe.

Products and services

  • Sample technologies (nucleic acid extraction)
  • QuantiFERON (TB testing)
  • QIAstat/PCR molecular diagnostics

Customers

  • Molecular diagnostic labs
  • Academic/government research labs
  • Biopharma companies

Where it sits in the supply chain

  • Healthcare/Life Sciences
  • Molecular diagnostics/genomics tools
  • Sample prep and molecular testing

What could go right

  • QuantiFERON TB test volume growth
  • Molecular diagnostics menu expansion

What could go wrong

  • COVID-testing revenue normalization
  • Academic/government funding cycle sensitivity

Moat: narrow (installed base, switching costs, IP / patents). Entrenched sample-prep technology embedded in customers' validated workflows across research and diagnostics.

Headquarters: Venlo, Netherlands · Founded: 1984 · Employees: 5,654

Named competitors

Qiagen at a glance

Size Qiagen (QGEN) is a United States Health Care company (Medical Specialties) with a market value of $10.2B, the 753rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $49.56 on 18 Nov 2026.

Performance Over six months the shares gained 41.2%, against +27.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 2.2% over the last twelve months (peer median +7.2%); the operating margin is 25.1% (peer median 13.7%).

Valuation It trades at 19.5× forward earnings against a peer median of 20.6× (10th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.3 points above its cost of capital (7.5% WACC).

Short interest Short interest is 3.1% of the free float (30 Oct 2026).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026QGEN 142Peer median 127
Six months, rebased to 100: Qiagen against the median of its 20 peers (local-currency closes).

Qiagen financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.12B$2.09B$1.98B$1.97B$2.14B
Revenue growth—+6%+1%-8%—
Gross profit$1.32B$1.29B$1.25B$1.22B$1.37B
EBITDA$736M$735M$698M$651M$785M
Net income$385M$425M$83.6M$341M$423M
Free cash flow$436M$453M$506M$310M$586M
Capital expenditure$203M$207M$171M$163M$149M
Total debt$1.64B$1.81B$1.51B$1.61B$1.96B

Quarterly statements and history in the cockpit →

Qiagen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%+20%DEMANTAVTRBIOPODDBRKRGMEDCOOALGNBIMSNPEN77016869BAXLENSKARTGKOS300832GETI-BBLCOQGEN6-month return →1-month return →
Up and to the right = strong over both horizons. Qiagen is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×DEMANTAVTRBIOPODDBRKRGMEDCOOBIMPEN77336869LENSKARTGKOS300832GETI-BQGENRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Qiagen is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%DEMANTAVTRBIOPODDBRKRGMEDCOOALGNPEN773377016869BAXLENSKART300832GETI-BQGENGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Qiagen is the large dot.

Qiagen competitors and peer comparison

Head to head with its named competitors (QGEN vs TMO vs DHR vs ILMN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Qiagen QGEN$10.2B+41%+2%25%19.5×8.6%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Illumina ILMN$31.8B+48%+6%21%35.2×27.2%

How Qiagen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Qiagen against its 20 peers (data as of 18 Nov 2026)
MeasureQGENPeer medianRank in peer set
1-month return+1.4%+6.1%7th lowest of 21
6-month return+41.2%+27.4%6th highest of 21
Distance from 52-week high-14.3%-11.1%8th lowest of 21
Revenue growth (TTM)+2.2%+7.2%7th lowest of 21
Operating margin25.1%13.7%2nd highest of 21
Forward P/E19.5×20.6×10th cheapest of 21
Growth the price implies (Req g, 7 yrs)8.6%10.6%9th least demanding of 20
Growth delivered (Del g)+2.2%+10.0%4th lowest of 20
Hurdle (Req g minus delivered)+6.4 pp+2.0 pp7th most demanding of 20
ROIC minus cost of capital+2.3 pp+2.4 pp10th lowest of 21
EV / EBITDA15.0×12.4×5th most expensive of 19
Net debt / EBITDA1.1×0.6×9th most indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%

Questions

Who are Qiagen's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Roche Diagnostics (private or unlisted), Danaher Corporation (DHR), Illumina (ILMN). The cockpit's measured peer set (industry) also includes Demant A/S (DEMANT.CO), Avantor (AVTR), Bio-Rad Laboratories (BIO), Insulet (PODD), Bruker (BRKR), Globus Medical (GMED).
Is Qiagen expensive compared with its peers?
On forward p/e it trades at 19.5× against a peer median of 20.6×, 10th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Qiagen stock performed?
Over six months to 18 Nov 2026 the shares returned +41.2% against +27.4% for the median peer; over one year +6.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.